Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates
To highlight differentiated drug discovery capabilities with its Generative Phosphoproteomics AP3 platform and program updates from the Phase 2b study of ACR-368 and Phase 1 study of ACR-2316
WATERTOWN, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ('Acrivon' or 'Acrivon Therapeutics') (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics (AP3) platform for the discovery, design, and development of drug candidates through a mechanistic match to patients whose disease is predicted sensitive to the specific treatment, announced it will be holding a virtual R&D event on March 25, 2025 from 4:00 p.m. to 5:15 p.m. ET. The agenda will feature presentations by Acrivon's leadership and founding team and endometrial cancer key opinion leaders, followed by a Q&A session.
Key Opinion Leader Participants:
Mansoor Raza Mirza, M.D., chief oncologist at Copenhagen University Hospital, Denmark; medical director of the Nordic Society of Gynecologic Oncology-Clinical Trial Unit (NSGO-CTU); vice president of the European Society of Gynecological Oncology (ESGO); board of directors, Gynecologic Cancer Inter-Group (GCIG)
Robert L. Coleman, M.D., co-director of the Gynecologic Oncology Group (GOG) Partners Foundation, Inc.; chief medical officer at Vaniam Group
Jesper Olsen, Ph.D., professor at the University of Copenhagen; deputy director at the Novo Nordisk Foundation Center for Protein Research; academic co-founder of Acrivon
A live webcast of the event will be available through a link on the Events & Presentations page within the investor section of the company's website at https://ir.acrivon.com/news-events/events-presentations. The webcast will be available for at least 30 days following the event.
About Acrivon Therapeutics Acrivon is a clinical stage biopharmaceutical company discovering and developing precision oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics, or AP3. The AP3 platform is engineered to measure compound-specific effects on the entire tumor cell protein signaling network and drug-induced resistance mechanisms in an unbiased manner yielding terabytes of high resolution proprietary quantitative data for pathway-based drug design, indication finding, and response prediction. These distinctive capabilities enable AP3's direct application for streamlined rational drug discovery for monotherapy activity, the identification of rational drug combinations, and the creation of drug-specific proprietary OncoSignature companion diagnostics that are used to identify the patients most likely to benefit from Acrivon's drug candidates. Acrivon is currently advancing its lead candidate, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial across multiple tumor types. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as monotherapy based on OncoSignature-predicted sensitivity in patients with platinum-resistant ovarian or endometrial cancer. Acrivon's ACR-368 OncoSignature test, which has not yet obtained regulatory approval, has been extensively evaluated in preclinical studies, including in two separate, blinded, prospectively-designed studies on pretreatment tumor biopsies collected from past third-party Phase 2 trials in patients with ovarian cancer treated with ACR-368. The FDA has granted Breakthrough Device designations for the ACR-368 OncoSignature assay for the identification of patients with endometrial cancer or for patients with ovarian cancer, who may benefit from ACR-368 treatment.
In addition to ACR-368, Acrivon is also leveraging its proprietary AP3 precision medicine platform for developing its co-crystallography-driven, internally discovered pipeline programs. These include ACR-2316, the company's second clinical stage asset, a novel, potent, selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity through strong activation of not only CDK1 and CDK2, but also of PLK1 to drive pro-apoptotic cell death, as demonstrated in preclinical studies against benchmark inhibitors. In addition, the company has a preclinical cell cycle program with an undisclosed target.
Acrivon has developed its AP3 Interactome, a proprietary, computational analytics platform driven by Generative Phosphoproteomics machine learning for integrated comprehensive analyses across all large, in-house AP3 phosphoproteomic drug profiling data sets to advance its in-house research programs.
Forward-Looking Statements This press release includes certain disclosures that contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, preclinical and clinical results, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Acrivon's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled 'Risk Factors' in our reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Acrivon undertakes no duty to update such information except as required under applicable law.
Investor and Media Contacts: Adam D. Levy, Ph.D., M.B.A.alevy@acrivon.com
Alexandra Santos asantos@wheelhouselsa.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 hours ago
- Yahoo
Air Canada flight attendants walk off the job as strike begins
More than 10,000 Air Canada flight attendants went on strike as of 12:58 a.m. ET Saturday, after the airline and the union representing them failed to reach a deal ahead of the deadline. The Canadian Union of Public Employees, or CUPE, gave a 72-hour strike notice on Wednesday after midnight. Air Canada responded shortly after by saying it would lock out workers, and began winding down operations on Thursday with a gradual suspension of flights. With a work stoppage now in effect, Air Canada estimates that 130,000 customers will be affected each day of a strike, a figure that includes 25,000 Canadian travellers who are abroad. The strike began after talks between CUPE and Air Canada reached an impasse, with wages and ground pay — which compensates flight attendants for work while the plane is grounded — among the key sticking points keeping the parties from reaching a deal. Earlier this week, Air Canada formally proposed to CUPE that the parties use binding arbitration to negotiate the renewal of a 10-year collective agreement that expired in March. CUPE declined to use arbitration, a process that would have an arbitrator render a decision about specific items the parties can't agree on. CUPE has maintained it wants to stay at the negotiating table and have the two sides come to an agreement themselves. Air Canada asked federal Jobs Minister Patty Hajdu to make a referral under Section 107 of the Canada Labour Code to send the negotiations to binding interest arbitration. Hajdu gave CUPE until noon on Friday to respond, and they declined. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
16 hours ago
- Yahoo
Bullish stock ends first day at $70 with 90% gain, giving crypto exchange market cap above $10 billion
Cryptocurrency exchange operator Bullish (BLSH) rose 12% on Thursday before the bell, reaching $78, doubling its IPO price of $37 and valuing the company at more than $10 billion. Still, this marked around a 16% drop from where the stock opened for trade. Bullish stock opened for trade at $90 near 1:00 p.m. ET on Wednesday, and the stock traded hands as high as $118 per share shortly after, a more than 215% gain. The stock was halted for trade due to volatility at least twice within the first few minutes of trading. The company, which operates a crypto exchange and owns the prominent trade publication CoinDesk, priced its IPO at $37 per share on Tuesday, above the $32 to $33 range the company had expected in its second shot at making a public market debut. Bullish began its IPO process looking for a price between $28 and $31 per share. At 30 million shares offered, the IPO price saw Bullish raise $1.1 billion and value the fintech company at $5.41 billion. Bullish first attempted to go public via a SPAC merger in 2021 that would have valued the company at $9 billion, but the deal fell through after regulatory scrutiny, and Bullish withdrew its registration. The company's debut rode the outsized success of recent go-publics like Figma (FIG) and Circle (CRCL) and served as the latest sign that the IPO window remains wide open after a few challenging years for investors. Through Wednesday, 2025 has so far seen 133 IPOs come to market worth more than $50 million, up more than 58% from the same time last year, according to IPO tracker and ETF operator Renaissance Capital. Ahead of its IPO, Bullish also garnered major institutional interest. Asset management giant BlackRock and Cathie Wood's investment firm Ark Invest expressed interest in purchasing up to $200 million worth of shares in the offering, according to securities filings. "We now intend to IPO because we believe that the digital assets industry is beginning its next leg of growth," Bullish CEO Thomas Farley, previously COO and president of the NYSE Group, wrote in a letter to investors about Bullish's offering. "I believe that the digital assets industry is at the inflection point of institutional adoption, and Bullish is uniquely positioned at the center of this market. The compliant, institutional-focused market infrastructure model is time-tested and works, and Bullish is proud to be the one bringing this proven framework to the crypto landscape." Read more: Can you buy crypto with a credit card? See the pros and cons. Bullish's main business comes from its Bullish Exchange, a digital assets spot and derivative exchange geared toward institutional-sized clients. The operator processed an average $2.6 billion in daily volume through Q1, according to the company's prospectus. When USDC stablecoin manager Circle Internet Group went public in June, its shares soared by 168% in their first day of trading. And while the price has come down, the stock is still up more than 120% since inception. Design software maker Figma popped even higher in its end-of-July offering, rocketing upward by more than 250% in its first day, though its price has now come back to earth, down more than 3% since inception. AI infrastructure provider CoreWeave (CRWV) is up more than 200% since its March debut after losing more than 20% on Wednesday. Digital assets and blockchain services firm Galaxy Digital (GLXY) is up more than 20% since its own May offering. Bullish is also riding a rally in major cryptocurrencies this year. Bitcoin (BTC-USD) is up more than 30% since the beginning of the year, and ETH (ETH-USD) is up more than 40%. Ripple's XRP (XRP-USD) is up more than 57%. The public offering comes as the latest sign that Wall Street's prediction for a lethargic IPO market in 2025 was off the money. Jake Conley is a breaking news reporter covering US equities for Yahoo Finance. Follow him on X at @byjakeconley or email him at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 hours ago
- Yahoo
Air Canada flight attendants walk off the job as strike begins
More than 10,000 Air Canada flight attendants went on strike as of 12:58 a.m. ET Saturday, after the airline and the union representing them failed to reach a deal ahead of the deadline. The Canada Union of Public Employees, or CUPE, gave a 72-hour strike notice on Wednesday after midnight. Air Canada responded shortly after by saying it would lock out workers, and began winding down operations on Thursday with a gradual suspension of flights. With a work stoppage now in effect, Air Canada estimates that 130,000 customers will be affected each day of a strike, a figure that includes 25,000 Canadian travellers who are abroad. The strike began after talks between CUPE and Air Canada reached an impasse, with wages and ground pay — which compensates flight attendants for work while the plane is grounded — among the key sticking points keeping the parties from reaching a deal. Earlier this week, Air Canada formally proposed to CUPE that the parties use binding arbitration to negotiate the renewal of a 10-year collective agreement that expired in March. CUPE declined to use arbitration, a process that would have an arbitrator render a decision about specific items the parties can't agree on. CUPE has maintained it wants to stay at the negotiating table and have the two sides come to an agreement themselves. Air Canada asked federal Jobs Minister Patty Hajdu to make a referral under Section 107 of the Canada Labour Code to send the negotiations to binding interest arbitration. Hajdu gave CUPE until noon on Friday to respond, and they declined. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
